Transient Neonatal Myasthenia Gravis
Immunology·MeSH: Spinocerebellar ataxia 23
Prevalence
20.0 / 100K
Incidence
1.7 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Transient Neonatal Myasthenia Gravis?
There are 1 clinical trial targeting Transient Neonatal Myasthenia Gravis tracked by BioSniper.
What is the prevalence of Transient Neonatal Myasthenia Gravis?
The estimated prevalence of Transient Neonatal Myasthenia Gravis is approximately 20.0 per 100,000 population.
Deep-dive into Transient Neonatal Myasthenia Gravis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis